| KTB TUMORFORSCHUNGSGESELLSCHAFT MBH Patent applications |
| Patent application number | Title | Published |
|---|
| 20120094892 | PRODRUGS - The present invention relates to a prodrug comprising at least one cytostatic agent, wherein said prodrug is cleavable by prostate-specific antigen (PSA), a process for preparing said prodrug and a pharmaceutical composition containing said prodrug in a pharmaceutically effective amount, for use in the treatment of cancer. | 04-19-2012 |
| 20110117009 | DRUG CONJUGATES WITH POLYGLYCEROLS - The present invention relates to a drug polymer conjugate comprising a pharmaceutically active compound and a dendritic polyglycerol, as well as to a drug polymer conjugate comprising a pharmaceutically and/or diagnostically active compound bound to a dendritic polyglycerol core having a polyethylene glycol shell. | 05-19-2011 |
| 20100152273 | LOW-VISCOUS ANTHRACYCLINE FORMULATION - The present invention relates to formulations comprising an anthracycline compound and an aromatic or heterocyclic compound. | 06-17-2010 |
| 20100144647 | Dual Acting Prodrugs - The present invention relates to a prodrug which comprises at least two different pharmaceutically and/or diagnostically active compounds independently bound by cleavable linkers and a protein-binding moiety which is capable of binding to carrier a molecule. | 06-10-2010 |
| 20100111866 | Receptor and Antigen Targeted Prodrug - The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety and a protein-binding moiety which is capable of binding to a carrier molecule. | 05-06-2010 |
| 20090298793 | Acylgycerophospholipids for treating symptoms concomitant with cancer - The invention relates to the use of acylglycerophospholipids, in particular of hydrogenated acylglycerophospholipids and of phospholipids with a high omega-3 fatty acid content, for the production of a medicament for treating symptoms concomitant with cancer, in particular for treating tumour cachexia, cancer-related problems and pain, and for the prophylaxis of tumour growth and metastasis. | 12-03-2009 |
